Safety, reactogenicity and immunogenicity of meningococcal vaccine group B OMV Novartis (NIPH-MeNZB) compared to meningococcal vaccine-group-B-OMV parent vaccine (MenBvac) in children.
Phase of Trial: Phase II
Latest Information Update: 30 Oct 2014
At a glance
- Drugs Meningococcal vaccine group B OMV Novartis (Primary) ; Meningococcal vaccine group B OMV
- Indications Meningococcal infections
- Focus Pharmacodynamics
- 30 Oct 2014 Primary endpoint 'number of patients with seroresponce' has been met, according to an abstract presented at the 44th Interscience Conference on Antimicrobial Agents and Chemotherapy.
- 05 Nov 2010 New trial record.